ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO1108

The Severity of Microscopic Hematuria in IgA Nephropathy Correlates with the Incidence of Gross Hematuria Following SARS-CoV-2 mRNA Vaccination

Session Information

  • COVID-19 - I
    November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Yokote, Shinya, Tokyo Jikeikai Ika Daigaku, Minato-ku, Tokyo, Japan
  • Tsuboi, Nobuo, Tokyo Jikeikai Ika Daigaku, Minato-ku, Tokyo, Japan
  • Shimizu, Akihiro, Tokyo Jikeikai Ika Daigaku, Minato-ku, Tokyo, Japan
  • Okabe, Masahiro, Tokyo Jikeikai Ika Daigaku, Minato-ku, Tokyo, Japan
  • Haruhara, Kotaro, Tokyo Jikeikai Ika Daigaku, Minato-ku, Tokyo, Japan
  • Sasaki, Takaya, Tokyo Jikeikai Ika Daigaku, Minato-ku, Tokyo, Japan
  • Ueda, Hiroyuki, Tokyo Jikeikai Ika Daigaku, Minato-ku, Tokyo, Japan
  • Yokoo, Takashi, Tokyo Jikeikai Ika Daigaku, Minato-ku, Tokyo, Japan
Background

Since the initiation of a global vaccination program against the COVID-19 pandemic, numerous cases of newly diagnosed or worsening immunoglobulin A nephropathy (IgAN) with gross hematuria have been reported following SARS-CoV-2 mRNA vaccination. Recent case studies have indicated a possible link between baseline urinary findings and the appearance of gross hematuria following SARS-CoV-2 mRNA vaccination.

Methods

Outpatients with biopsy-proven IgAN aged 18 years or older were included in this study. The association between pre-vaccination microscopic hematuria (urine sediment < 5 /HPF) or proteinuria (< 0.3 g/gCr) and post-vaccination gross hematuria was retrospectively analyzed.

Results

A total of 417 IgAN patients (mean age, 51 years; 56 % female; eGFR, 58 mL/min/1.73 m2) were included. The frequency of post-vaccination gross hematuria was higher in patients (20/123; 16.3%) with pre-vaccination microscopic hematuria than in patients (5/294; 1.7%) without pre-vaccination microscopic hematuria (p < 0.001). There was no association between pre-vaccination proteinuria and post-vaccination gross hematuria. After adjustment for potential confounders such as gender (female), age group (< 50 years), eGFR category (≥ 60 mL/min/1.73m2), and prior tonsillectomy or corticosteroid therapy, microscopic hematuria was still associated with post-vaccination gross hematuria (OR 8.98, p < 0.001). Notably, as the severity of pre-vaccination microscopic hematuria increased, the incidence of post-vaccination gross hematuria increased (Figure 1).

Conclusion

These results suggest that baseline microscopic hematuria predicts gross hematuria after SARS-CoV-2 mRNA vaccination in patients already diagnosed with IgAN. The correlation between the severity of pre-vaccination microscopic hematuria and the incidence of post-vaccination gross hematuria suggests that IgAN disease activity is involved in this association.